EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

ANODYNE study: A double-blind randomized trial of greater occipital nerve block of methylprednisolone and lignocaine versus placebo as a transitional preventive treatment for episodic cluster headache

Debashish Chowdhury iD, Sanjay Rao Kordcal iD, Rahul Nagane, Ashish Duggal

Cephalalgia · 2024

DOI: 10.1177/03331024241291597 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, 2024. Verfasst von Debashish Chowdhury und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India. Hauptthemen laut MEDLINE: Lidocaine, Methylprednisolone, Nerve Block, Anesthetics, Local. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is inadequate evidence of the efficacy of greater occipital nerve block (GONB) for the preventive treatment of cluster headaches. We assessed the efficacy and tolerability of GONB injections as a transitional preventive treatment for episodic cluster headaches (ECH).

Methods

This randomized, double-blind, placebo-controlled, parallel-group trial conducted at GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India, included ECH patients diagnosed by ICHD-3 criteria, aged 18–65, with one or more attacks per 24 h for seven days before randomization (baseline). ECH patients were either not on preventive medications or on stable doses for at least three months. ECH patients were randomized to receive active GONB (2 ml methylprednisolone (80 mg) and 2 ml lignocaine (2%)) and placebo (4 ml saline injections). Before giving GONB, lignocaine jelly was applied topically to mask the effect of numbness following the GONB. The primary efficacy endpoint was the mean change in weekly attack frequency from baseline to Week 4. Efficacy analyses were performed in a modified intention-to-treat population that included all patients who received at least one injection of GONB and had a follow-up for one week following GONB. The safety analysis included treatment-emergent adverse effects (TEAE) in all patients who received at least one dose of investigational product. The trial was registered with the Clinical Trials Registry of India (CTRI/2021/21/038397).

Results

Forty ECH patients were randomized between December 2021 and January 2023. Thirty-nine patients (19 in the active and 20 in the placebo groups) were available for efficacy analysis. The change in weekly attack frequency from baseline to Week 4 was −11.1 (95% CI: −8.5 to −4.4) for the active group compared to −7.7 (95% CI: −11.8 to −9.8) for placebo (mean difference −3.4 (95% CI: −5.2 to −1.7, p < 0.001). We noted TEAE in 18 (90%) of 20 patients who received the active drug and in 18 (90%) of 20 patients who received a placebo ( p = 0.38). The common TEAE were local site bleeding and pain, which were mild and transient. No serious adverse events were reported.

Conclusion

This study found that GONB with methylprednisolone and lignocaine significantly reduced the weekly attack frequency from baseline to Week 1 through Week 4 in ECH patients compared to a placebo. GONB was well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LidocaineMethylprednisoloneNerve BlockAnesthetics, LocalCluster HeadacheHumansDouble-Blind MethodMaleAdultFemaleMiddle AgedYoung AdultAdolescentAgedTreatment Outcome

Stichwörter der Autor:innen

cluster headacheepisodic cluster headachegreater occipital nerve blockmethylprednisolonepatient reported outcometransitional treatment

Substanzen

LidocaineMethylprednisoloneAnesthetics, Local

Autor:innen und Institutionen

  • Department of Neurology, GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India.

ORCID-Profile: Debashish Chowdhury, Sanjay Rao Kordcal

Zitieren

APA

Chowdhury, D., Kordcal, S. R., Nagane, R., & Duggal, A. (2024). ANODYNE study: A double-blind randomized trial of greater occipital nerve block of methylprednisolone and lignocaine versus placebo as a transitional preventive treatment for episodic cluster headache. Cephalalgia. https://doi.org/10.1177/03331024241291597

Vancouver

Chowdhury D, Kordcal SR, Nagane R, Duggal A. ANODYNE study: A double-blind randomized trial of greater occipital nerve block of methylprednisolone and lignocaine versus placebo as a transitional preventive treatment for episodic cluster headache. Cephalalgia. 2024. doi:10.1177/03331024241291597

BibTeX
@article{Chowdhury2024,
  author = {Chowdhury, Debashish and Kordcal, Sanjay Rao and Nagane, Rahul and Duggal, Ashish},
  title = {ANODYNE study: A double-blind randomized trial of greater occipital nerve block of methylprednisolone and lignocaine versus placebo as a transitional preventive treatment for episodic cluster headache},
  journal = {Cephalalgia},
  year = {2024},
  doi = {10.1177/03331024241291597}
}
Kostenlos starten →